Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies.

Autor: Schmidt MS; College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA., King CL; School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA., Thomsen EK; Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK., Siba PM; Papua New Guinea Institute for Medical Research, Papua New Guinea., Sanuku N; Papua New Guinea Institute for Medical Research, Papua New Guinea., Fleckenstein L; College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA. Electronic address: l-fleckenstein@uiowa.edu.
Jazyk: angličtina
Zdroj: Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2014 Sep; Vol. 98, pp. 307-10. Date of Electronic Publication: 2014 May 22.
DOI: 10.1016/j.jpba.2014.05.016
Abstrakt: A sensitive and selective liquid chromatographic method using mass spectrometric detection was developed for the determination of diethylcarbamazine (DEC) in human plasma. DEC and its stable isotope internal standard d3-DEC were extracted from 0.25mL of human plasma using solid phase extraction. Chromatography was performed using a Phenomenex Synergi 4μ Fusion-RP column (2mm×250mm) with gradient elution. The retention time was approximately 4.8min. The assay was linear from 4 to 2200ng/mL. Analysis of quality control samples at 12, 300, and 1700ng/mL (N=15) had interday coefficients of variation of 8.4%, 5.4%, and 6.2%, respectively (N=15). Interday bias results were -2.2%, 6.0%, and 0.8%, respectively. Recovery of DEC from plasma ranged from 84.2% to 90.1%. The method was successfully applied to clinical samples from patients with lymphatic filariasis from a drug-drug interaction study between DEC and albendazole and/or ivermectin.
(Copyright © 2014 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: